METHODS AND COMPOSITIONS FOR EVALUATING BREAST CANCER PATIENTS

摘要

Embodiments are directed to methods of evaluating the prognosis of a breast cancer patient by assessing the level of phosphorylation tyrosine 36 of estrogen receptor beta (ERB). Certain embodiments are directed to methods for evaluating the prognosis of a cancer patient comprising contacting a breast cancer sample from a patient with stage II or stage III breast cancer with an antibody that binds phosphorylated tyrosine 36 of Εί¾β; quantifying phosphorylation of tyrosine 36 of ΕΙ¾β; and classifying the patient as having a good prognosis if phosphorylated tyrosine 36 levels are elevated or classifying the patient as having a poor prognosis if tyrosine levels are decreased relative to a non-cancer control. Certain embodiments are directed to an antibody or antibodies that specifically bind tyrosine 36 (Y36) of the ERp.